Janusq LLC

Janusq LLC is a startup biotechnology company spun out of Case Western Reserve University, focused on developing innovative peptide-based therapies targeting neurodegenerative diseases. Specializing in advanced medical research, the company concentrates on addressing mitochondrial dysfunction associated with conditions like Alzheimer's disease and Huntington's disease through sophisticated peptide interventions.

The company has secured multiple federal grants from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, totaling over $1 million in funding for targeted research projects. These grants support the development of specific peptide therapies, including DA1, DA45, and HV-3, which aim to disrupt protein interactions and mitigate mitochondrial dysfunction in neurodegenerative conditions. Each research project involves comprehensive pharmacokinetic assessments, in vivo efficacy studies, and safety evaluations using mouse models. The grants, structured as Small Business Innovation Research (SBIR) awards, enable Janusq to investigate peptide stability, brain tissue penetration, and potential therapeutic impacts on neurological disorders. The research focuses on understanding molecular mechanisms of diseases like Alzheimer's and Huntington's, with the ultimate goal of developing potential treatment strategies that address underlying cellular dysfunction rather than just managing symptoms.